Effects of synthetic oligonucleotides on human complement and coagulation

Biochemical Pharmacology

Volumn 53, Issue 8, 1997, Pages 1123-1132

  Shaw, Denise R ^a,b,c   Rustagi, Pradip K ^a   Kandimalla, Ekambar R ^d   Manning, Adrienne N ^d   Jiang, Zhiwei ^d   Agrawal, Sudhir ^d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HYBRIDON INC   (United States)

Author keywords

antisense oligodeoxynucleotide; coagulation; complement; phosphorothioate

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENT COMPONENT C4D; HEPARIN; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTAMINE SULFATE; PROTHROMBIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEMOLYSIS; HUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BLOOD; BLOOD COAGULATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOLYSIS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PARTIAL THROMBOPLASTIN TIME; PROTAMINES; THIONUCLEOTIDES;

EID: 0031006756     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00091-9     Document Type: Article

References (36)

1. Zamecnik PC, Oligonucleotide base hybridization as a modulator of genetic message readout. In: Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Ed. Wickstrom E), pp. 1-6. Wiley-Liss, New York, 1991.
2. Agrawal S, Antisense oligonucleotides towards clinical trials. Trends Biotechnol 14: 376-387, 1996.
3. Agrawal S and Iyer RP, Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol 6: 12-19, 1995.
4. Agrawal S, Temsamani J, Galbraith W and Tang J, Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28: 7-16, 1995.
5. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45: 932-943, 1994.
6. Metelev V, Lisziewicz J and Agrawal S, Study of antisense oligonucleotide phosphorothioate containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg Med Chem Lett 4: 2929-2934, 1994.
7. Agrawal S, Mayrand SH, Zamecnik PC and Pederson T, Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides. Proc Natl Acad Sci USA 87: 1401-1405, 1990.
8. Tang JY, Temsamani J and Agrawal S, Self-stabilized anti-sense oligodeoxynucleotide phosphorothioates: Properties and anti-HIV activity. Nucleic Acids Res 21: 2729-2735, 1993.
9. Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z and Agrawal S, In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem 41: 836-843, 1995.
10. Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D and Agrawal S, In vivo stability, disposition and metabolism of a hybrid oligonucleotide phosphorothioate in rats. Biochem Pharmocol 50: 545-556, 1995.
11. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I and Jiang Z, Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50: 571-576, 1995.
12. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM and Agrawal S, Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939, 1995.
13. Agrawal S, Temsamani J and Tang JY, Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599, 1991.
14. Iversen PL, Mata J, Tracewell WG and Zon G, Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev 4: 43-52, 1994.
15. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J and Martin RR, Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58: 44-53, 1995.
16. Bayever E, Iverson PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G and Armitage JO, Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res Dev 3: 383-390, 1993.
17. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ and Agrawal S, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4: 201-206, 1994.
18. Cornish KG, Iverson P, Smith L, Arneson M and Bayever E, Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun 3: 239-247, 1993.
19. Henry SP, Larkin R, Novonty WF and Kombrust DJ, Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharm Res 11: S-353, 1994.
20. Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC and Agrawal S, Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA 91: 7942-7946, 1994.
21. Padmapriya AA, Tang J and Agrawal S, Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res Dev 4: 185-199, 1994.
22. Zhang R, Iyer RP, Yu D, Tan W, Zhang X, Lu Z, Zhao H and Agrawal S, Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther 278: 971-979, 1996.
23. Sambrook J, Fritsch EF and Maniatis T, Molecular Cloning - A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
24. Mayer MM, Complement and complement fixation. In: Experimental Immunochemistry (Eds. Kabat EA and Mayer MM), pp. 125-131. C. C. Thomas, Springfield, 1961.
25. van Schravendijk MR and Dwek RA, Interaction of C1q with DNA. Mol Immunol 19: 1179-1187, 1982.
26. Jiang H, Cooper B, Robey FA and Gewurz H, DNA binds and activates complement via residues 14-26 of the human C1q A chain. J Biol Chem 267: 25597-25601, 1992.
27. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G and Gewirtz AM, Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci USA 91: 4499-4503, 1994.
28. Szorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iverson P, Iozzo RV, Zon G and Calbretta B, Suppression of Philadelphia 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91: 4504-4508, 1994.
29. 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 56: 641-646, 1994.
30. Frey PA and Sammons RD, Bond order and charge localization in nucleoside phosphorothioates. Science 228: 541-545, 1985.
31. Jiang H, Robey FA and Gewurz H, Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med 175: 1373-1379, 1992.
32. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM, CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
33. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ and Leung LLK, In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81: 3271-3276, 1993.
34. Bock LC, Griffin LC, Latham JA, Vermaas EH and Toole JJ, Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355: 564-566, 1992.
35. Stein CA and Chang Y, Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science 261: 1004-1012, 1993.
36. Srinivasan SK, Tewary HK and Iverson PL, Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 5: 131-139, 1995.